Rajabali Daroudi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2627763/publications.pdf

Version: 2024-02-01

840776 752698 31 447 11 20 citations h-index g-index papers 39 39 39 590 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Health impact and related cost of ambient air pollution in Tehran. Environmental Research, 2019, 176, 108547.	7.5	112
2	The Economic Burden of Breast Cancer in Iran. Iranian Journal of Public Health, 2015, 44, 1225-33.	0.5	40
3	Health-related quality of life measured using the EQ-5D–5 L: population norms for the capital of Iran. Health and Quality of Life Outcomes, 2020, 18, 108.	2.4	34
4	Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds. Cost Effectiveness and Resource Allocation, 2021, 19, 7.	1.5	28
5	Years of Potential Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Iran. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1845-1850.	1.2	26
6	A Systematic Review of Economic Aspects of Cervical Cancer Screening Strategies Worldwide: Discrepancy between Economic Analysis and Policymaking. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8229-8237.	1.2	25
7	Determinants of healthcare expenditures in Iran: evidence from a time series analysis. Medical Journal of the Islamic Republic of Iran, 2016, 30, 313.	0.9	22
8	Economic burden of colorectal cancer in Iran in 2012. Medical Journal of the Islamic Republic of Iran, 2017, 31, 768-773.	0.9	21
9	Extent, nature and hospital costs of fireworks-related injuries during the Wednesday Eve Festival in Iran. Journal of Injury and Violence Research, $2013, 5, 11$ -6.	0.4	18
10	Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer. PLoS ONE, 2016, 11, e0156705.	2.5	17
11	Economic burden of medication-overuse headache in Iran: direct and indirect costs. Neurological Sciences, 2021, 42, 1869-1877.	1.9	11
12	Economic Burden of Gynecological Cancers in Iran. Value in Health Regional Issues, 2022, 28, 1-6.	1.2	11
13	Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran. BMC Public Health, 2021, 21, 926.	2.9	10
14	Direct costs of common osteoporotic fractures (Hip, Vertebral and Forearm) in Iran. BMC Musculoskeletal Disorders, 2021, 22, 651.	1.9	10
15	A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8229-37.	1.2	10
16	Life and health satisfaction in the adult population of Iran. Epidemiology and Health, 2016, 38, e2016047.	1.9	9
17	Estimation of the prevalence and direct medical costs of chronic myeloid leukemia in the I.R. of Iran in the era of tyrosine kinase inhibitors. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e416-e422.	1.1	6
18	The economic burden of osteoporosis in Iran in 2020. Osteoporosis International, 2022, 33, 2337-2346.	3.1	6

#	Article	IF	CITATIONS
19	Mothers' preferences and willingness-to-pay for human papillomavirus vaccines in Iran: A discrete choice experiment study. Preventive Medicine Reports, 2021, 23, 101438.	1.8	5
20	The impact of common chronic conditions on health-related quality of life: a general population survey in Iran using EQ-5D-5L. Cost Effectiveness and Resource Allocation, 2021, 19, 28.	1.5	4
21	Assessment of Utility in Migraine: Mapping the Migraine-Specific Questionnaire to the EQ-5D-5L. Value in Health Regional Issues, 2021, 25, 57-63.	1.2	4
22	Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs. International Journal of Health Policy and Management, 2016, 5, 99-105.	0.9	4
23	<p>Estimation of Generalized Impact Fraction and Population Attributable Fraction of Hypertension Based on JNC-IV and 2017 ACC/AHA Guidelines for Cardiovascular Diseases Using Parametric G-Formula: Tehran Lipid and Glucose Study (TLGS)</p> . Risk Management and Healthcare Policy. 2020. Volume 13. 1015-1028.	2.5	3
24	Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population. Archives of Iranian Medicine, 2017, 20, 564-571.	0.6	3
25	The Lost Productivity Cost of Premature Mortality Owing to Cancers in Iran: Evidence From the GLOBOCAN 2012 to 2018 Estimates. Value in Health Regional Issues, 2022, 31, 1-9.	1.2	2
26	Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran. Cost Effectiveness and Resource Allocation, 2021, 19, 29.	1.5	1
27	Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran. Iranian Journal of Public Health, 2018, 47, 567-574.	0.5	1
28	A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma. Cost Effectiveness and Resource Allocation, 2022, 20, 16.	1.5	1
29	The economic burden of esophageal cancer in Iran. Indian Journal of Cancer, 2022, 59, 499.	0.2	1
30	Economic Evaluation of Treatments for Patients with Esophageal Cancer: A Systematic Review. International Journal of Cancer Management, 2019, In Press, .	0.4	0
31	Healthcare Utilization and Expenditures among Iranian Chemical Warfare Survivors Exposed to Sulfur Mustard. Archives of Iranian Medicine, 2022, 25, 241-249.	0.6	0